FDA Looks To Outcomes Research In Move To Quantify Risk/Benefit Decisions
Executive Summary
Outcomes trials appear to hold a strong position in the future of new drug development. But outcomes data is not the only factor FDA will consider as it moves toward setting new standards for quantification of risk and benefit, the agency said at a recent drug safety conference
You may also be interested in...
Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA
The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference
Don’t Forget Injectable Insulin, Novo Nordisk Says
In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles
Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA
The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference